hyderabad, india — The pharmaceuticals export promotion council of india (Pharmexcil) has announced ambitious plans to conduct global business delegations in FY 2025-26, aiming to significantly boost indian pharmaceutical exports. this initiative comes at a critical time when the global demand for pharmaceuticals is surging, driven by an increased focus on healthcare and wellness.

Pharmexcil’s strategy is not just about expanding markets; it is about enhancing the global footprint of indian pharmaceutical companies. The organization plans to target key regions including north america, europe, and asia-Pacific, where demand for generic drugs and active pharmaceutical ingredients (APIs) is on the rise. this initiative is expected to open new avenues for indian manufacturers, allowing them to leverage their capabilities in producing high-quality medicines at competitive prices.

Why this initiative matters Now

The global pharmaceutical market is projected to reach $1.57 trillion by 2023, with a compound annual growth rate (cagr) of 4.5% from 2019 to 2023¹. As countries continue to recover from the COVID-19 pandemic, the demand for vaccines, therapeutics, and other medical supplies remains high. indian pharmaceutical companies, which already contribute significantly to global supplies, are well-positioned to capitalize on this trend. Pharmexcil’s initiative is crucial for ensuring that indian firms can compete effectively in this expanding market.

target markets and opportunities

Pharmexcil is focusing on several key markets, including the united states, which accounted for approximately 45% of global pharmaceutical sales in 2020². Additionally, europe remains a significant market, with a growing demand for generics and biosimilars. The asia-Pacific region is also emerging as a vital area for growth, driven by increasing healthcare expenditures and a rising middle class.

The asia-Pacific region is also emerging as a vital area for growth, driven by increasing healthcare expenditures and a rising middle class.

The council plans to facilitate partnerships between indian pharmaceutical companies and local distributors and healthcare providers in these regions. By establishing strong networks, indian firms can enhance their market penetration and brand visibility, ultimately leading to increased exports.

Supporting infrastructure and policy framework

For this initiative to succeed, a supportive infrastructure and policy framework are essential. The indian government has been proactive in enhancing the ease of doing business in the pharmaceutical sector. initiatives such as the production-linked Incentive (PLI) scheme aim to boost domestic manufacturing and attract foreign investment. Additionally, the government’s focus on improving regulatory compliance will help indian firms meet international standards, making them more competitive in global markets.

You may also like

Industry & Global Trends

China’s Consumer Shifts Redraw Global Auto Landscape

Chinese consumers are driving a global shift toward electric, connected cars, and forcing legacy automakers to adapt to new competitive realities, a trend we term…

Read More →

<figure class=”aligncenter”><img src="https://careeraheadonline.com/wp-content/uploads/2025/11/rI3eZpeeKvk.jpg" alt="Pharmexcil plans global business Delegations for FY 2025–26 to enhance indian pharma exports” loading=”lazy” />

challenges ahead for indian pharma

despite the opportunities, indian pharmaceutical companies face several challenges. regulatory hurdles, intellectual property issues, and intense competition from other countries such as china can hinder growth. Moreover, the increasing scrutiny on drug pricing and quality standards in international markets necessitates that indian firms invest in research and development to innovate and maintain compliance.

Furthermore, the geopolitical landscape can impact trade relations, making it crucial for indian companies to stay agile and adapt to changing conditions. Pharmexcil’s strategy must include risk mitigation plans to address these potential barriers.

Counterpoint: The need for caution

while the prospects for indian pharmaceutical exports appear promising, some experts urge caution. The global market is highly competitive, and success is not guaranteed. according to a report by the indian chamber of commerce, while indian firms have the potential to capture more market share, they must also contend with the increasing dominance of multinational corporations who are investing heavily in emerging markets³.

Additionally, the ongoing pandemic has highlighted vulnerabilities in global supply chains. firms must ensure that they have robust logistics and distribution channels in place to avoid disruptions. As the global landscape evolves, indian pharmaceutical companies must remain vigilant and adaptable to sustain their competitive edge.

The global market is highly competitive, and success is not guaranteed.

<div class=”sources-used” style=”font-size: 10px;color: #666;margin-top: 20px”>

<strong>Sources consulted:</strong> Pharmabiz, business Standard, indian Chamber of commerce, economic times

You may also like

Entrepreneurship & Business

Ecosystem Blind Spots Become Competitive Advantage

Entrepreneurs who broaden their risk view beyond internal metrics can turn hidden ecosystem threats into a strategic advantage, building resilience and sustained growth.

Read More →